Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hucMSCs in the Treatment of Premature Ovarian Insufficiency
NCT03816852Phase 2Suspended
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of human umbilical cord mesenchymal stem cells in premature ovarian insufficiency (POI) (3 arms), sponsored by Sclnow Biotechnology Co., Ltd. Primary endpoint: Menstrual changes at 270 days. Started Oct 2018; status: suspended.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT03816852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816852.